Furthermore, acquired resistance during the course of therapy due to whether resistant clonal selection by protective microenvironment, increased efflux of drug, or BCR-ABL signaling mechanism renders TKI ineffective for CML treatment [24–26]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.